Drugs / Allovectin-7®
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00044356 | Feb 2001 → Aug 2004 | melanoma, skin cancer | Vical | Completed | No outcome recorded |
| Phase 2 | NCT00003646 | Aug 1998 → Mar 2002 | melanoma | Vical | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00395070 | Oct 2006 → Mar 2012 | metastatic melanoma | Vical | Completed | No outcome recorded |
| Phase 3 | NCT00003647 | Jul 1998 → Sep 2002 | melanoma | Vical | Completed | No outcome recorded |
| Phase 3 | NCT00050388 | ? → Jun 2002 | head and neck squamous cell carcinoma | Vical | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allovectin-7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00050388 ↗ |
| Modality | Other / unclassified | “Allovectin-7®, an experimental gene-based immunotherapy” NCT00050388 ↗ |
| Route | Other | “Patients receive an intratumoral injection of Allovectin-7 once weekly for 6 weeks.” NCT00003646 ↗ |